Short Interest to Follow: What’s Verastem Incorporated (NASDAQ:VSTM) Upside After This Short Interest Decrease?

November 21, 2016 - By Nellie Frank   ·   0 Comments

Short Interest to Follow: What's Verastem Incorporated (NASDAQ:VSTM) Upside After This Short Interest Decrease?

The stock of Verastem Incorporated (NASDAQ:VSTM) registered a decrease of 53.36% in short interest. VSTM’s total short interest was 136,100 shares in November as published by FINRA. Its down 53.36% from 291,800 shares, reported previously. With 126,400 shares average volume, it will take short sellers 1 days to cover their VSTM’s short positions. The short interest to Verastem Incorporated’s float is 0.43%. The stock increased 0.81% or $0.01 on November 18, hitting $1.24. Verastem Inc (NASDAQ:VSTM) has declined 16.22% since April 19, 2016 and is downtrending. It has underperformed by 20.08% the S&P500.

Verastem, Inc. is a biopharmaceutical company. The company has a market cap of $45.50 million. The Firm is focused on discovering and developing drugs to improve outcomes for patients with cancer. It currently has negative earnings. The Firm operates in the segment of developing drugs for the treatment of cancer.

Insitutional Activity: The institutional sentiment decreased to 0.55 in 2016 Q2. Its down 0.01, from 0.56 in 2016Q1. The ratio is negative, as 18 funds sold all Verastem Inc shares owned while 25 reduced positions. 12 funds bought stakes while 12 increased positions. They now own 10.17 million shares or 21.93% less from 13.03 million shares in 2016Q1.
Wells Fargo & Mn has invested 0% of its portfolio in Verastem Inc (NASDAQ:VSTM). Moreover, Lpl Financial Ltd Liability Corp has 0% invested in Verastem Inc (NASDAQ:VSTM) for 17,852 shares. Connor Clark And Lunn Invest Management accumulated 231,075 shares or 0% of the stock. Blackrock Advsr Ltd reported 119,056 shares or 0% of all its holdings. Geode Capital Management Lc last reported 0% of its portfolio in the stock. Stifel Financial last reported 0% of its portfolio in the stock. The New York-based National Bank Of Ny Mellon has invested 0% in Verastem Inc (NASDAQ:VSTM). Pnc Svcs Incorporated reported 718 shares or 0% of all its holdings. Fmr Ltd accumulated 535,654 shares or 0% of the stock. Acadian Asset Mgmt Ltd Co has 0% invested in the company for 10,362 shares. Jacobs Levy Equity Management, a New Jersey-based fund reported 301,259 shares. Deer Vii And Communications Ltd has invested 0.7% of its portfolio in Verastem Inc (NASDAQ:VSTM). Moreover, Blackrock Inc has 0% invested in Verastem Inc (NASDAQ:VSTM) for 3,623 shares. Granite Point Cap Mngmt Limited Partnership has 137,550 shares for 0.08% of their US portfolio. Gru One Trading Ltd Partnership has 0% invested in the company for 66 shares.

Verastem Inc (NASDAQ:VSTM) Ratings Coverage

Out of 9 analysts covering Verastem (NASDAQ:VSTM), 2 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 22% are positive. Verastem has been the topic of 12 analyst reports since September 9, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating by Jefferies given on Tuesday, August 9. The company was downgraded on Monday, September 28 by Roth Capital. The rating was initiated by Raymond James on Wednesday, September 9 with “Strong Buy”. As per Tuesday, September 29, the company rating was downgraded by Cantor Fitzgerald. On Tuesday, September 29 the stock rating was downgraded by Jefferies to “Hold”. The company was downgraded on Monday, September 28 by Mizuho. TH Capital downgraded the shares of VSTM in a report on Monday, September 28 to “Neutral” rating. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, September 17 report. JMP Securities downgraded the stock to “Mkt Perform” rating in Tuesday, September 29 report. The stock has “Outperform” rating given by Raymond James on Tuesday, September 29.

VSTM Company Profile

Verastem, Inc., incorporated on August 4, 2010, is a biopharmaceutical company. The Firm is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Firm operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company’s programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Firm is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

More recent Verastem Inc (NASDAQ:VSTM) news were published by: Marketwatch.com which released: “Verastem Inc. NASDAQ: VSTM” on January 27, 2012. Also Bostonglobe.com published the news titled: “Verastem shares plunge as drug trial fails” on September 28, 2015. Fool.com‘s news article titled: “Verastem Inc.’s Upcoming Catalysts” with publication date: June 21, 2014 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Nellie Frank


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>